Particle-mediated delivery of cytokines for immunotherapy.

The ability of cytokines to direct the immune response to vaccination, infection and tumors has motivated their use in therapy to augment or shape immunity. To avoid toxic side effects associated with systemic cytokine administration, several approaches have been developed using particle-encapsulated cytokines to deliver this cargo to specific cell types and tissues. Initial work used cytokine-loaded particles to deliver proinflammatory cytokines to phagocytes to enhance antimicrobial and antitumor responses. These particles have also been used to create a cytokine depot at a local site to supplement prophylactic or antitumor vaccines or injected directly into solid tumors to activate immune cells to eliminate established tumors. Finally, recent advances have revealed that paracrine delivery of cytokines directly to T cells has the potential to enhance T-cell mediated therapies. The studies reviewed here highlight the progress in the last 30 years that has established the potential of particle-mediated cytokine immunotherapy.

[1]  D. Fan,et al.  Cytotoxic Potential of Liposomes Containing Tumor Necrosis Factor-α Against Sensitive and Resistant Target Cells , 1991, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[2]  Y. Barenholz,et al.  A novel influenza subunit vaccine composed of liposome-encapsulated haemagglutinin/neuraminidase and IL-2 or GM-CSF. II. Induction of TH1 and TH2 responses in mice. , 1999, Vaccine.

[3]  J. Imanishi,et al.  Enhancement of the protective effect of inactivated influenza virus vaccine by cytokines. , 1992, Vaccine.

[4]  E. Saravolac,et al.  Effect of liposome-encapsulation on immunomodulating and antiviral activities of interferon-γ☆ , 1996, Antiviral Research.

[5]  P. Wyde,et al.  Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2 liposomes. , 1990, Vaccine.

[6]  I. Fidler,et al.  Design of liposomes to improve delivery of macrophage-augmenting agents to alveolar macrophages. , 1980, Cancer research.

[7]  D. A. Eppstein,et al.  Partial dissociation of antiviral and antimitogenic activities of murine interferon after its incorporation into liposomes. , 1983, Journal of Interferon Research.

[8]  B. Narasimhan,et al.  Design of a Protective Single-Dose Intranasal Nanoparticle-Based Vaccine Platform for Respiratory Infectious Diseases , 2011, PloS one.

[9]  I. Fidler,et al.  Abrogation of species specificity for activation of tumoricidal properties in macrophages by recombinant mouse or human interferon-gamma encapsulated in liposomes. , 1985, Journal of immunology.

[10]  I. Fidler,et al.  Tumoricidal activity of human monocytes activated in vitro by free and liposome-encapsulated human lymphokines. , 1983, The Journal of clinical investigation.

[11]  D. Liggitt,et al.  Immunomodulatory and Toxic Effects of Free and Liposome-encapsulated Tumor Necrosis Factor α in Rats , 1990 .

[12]  D. Crommelin,et al.  Conformational stability of human interferon-gamma on association with and dissociation from liposomes. , 2000, Journal of pharmaceutical sciences.

[13]  W. M. Linehan,et al.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. , 1987, The New England journal of medicine.

[14]  J. Bystryn,et al.  Interleukin-2/liposomes potentiate immune responses to a soluble protein cancer vaccine in mice , 2006, Cancer Immunology, Immunotherapy.

[15]  Y. Barenholz,et al.  Immunogenicity and safety of a novel IL-2-supplemented liposomal influenza vaccine (INFLUSOME-VAC) in nursing-home residents. , 2003, Vaccine.

[16]  E. Butcher,et al.  The germinal center response is impaired in the absence of T cell‐expressed CXCR5 , 2007, European journal of immunology.

[17]  B. Amsden,et al.  Interferon‐γ therapy: Evaluation of routes of administration and delivery systems , 2002 .

[18]  H. Maeda,et al.  Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. , 2000, Journal of controlled release : official journal of the Controlled Release Society.

[19]  D. Pettit,et al.  Biodegradable polymers for protein and peptide drug delivery. , 1995, Bioconjugate chemistry.

[20]  M. C. Popescu,et al.  A novel proteoliposomal vaccine elicits potent antitumor immunity in mice. , 2007, Blood.

[21]  D. Longo,et al.  Antitumor effects of interleukin 2 liposomes and anti-CD3-stimulated T-cells against murine MCA-38 hepatic metastasis. , 1991, Cancer research.

[22]  Joseph M. DeSimone,et al.  Strategies in the design of nanoparticles for therapeutic applications , 2010, Nature Reviews Drug Discovery.

[23]  M. Baca-Estrada,et al.  Induction of mucosal immune responses by administration of liposome-antigen formulations and interleukin-12. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[24]  P. Morrissey,et al.  Characterization of Poly(glycolide-co-D,L-lactide)/Poly(D,L-lactide) Microspheres for Controlled Release of GM-CSF , 1997, Pharmaceutical Research.

[25]  A. Bagg,et al.  Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. , 2011, The New England journal of medicine.

[26]  S. Crotty,et al.  Follicular helper CD4 T cells (TFH). , 2011, Annual review of immunology.

[27]  P. Ellis,et al.  Updated survival analysis in patients with stage IIIB or IV non-small-cell lung cancer receiving BLP25 liposome vaccine (L-BLP25): phase IIB randomized, multicenter, open-label trial , 2011, Journal of Cancer Research and Clinical Oncology.

[28]  Gregory Gregoriadis,et al.  Liposomes As Immunological Adjuvants and Vaccine Carriers , 1996 .

[29]  E. Jaffee,et al.  Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. , 1993, Cancer research.

[30]  Peter Scheurich,et al.  Tumor necrosis factor (TNF)-functionalized nanostructured particles for the stimulation of membrane TNF-specific cell responses. , 2005, Bioconjugate chemistry.

[31]  J. Cleland,et al.  Stable Formulations of Recombinant Human Growth Hormone and Interferon-γ for Microencapsulation in Biodegradable Mircospheres , 1996, Pharmaceutical Research.

[32]  R. Debs,et al.  Liposome-associated tumor necrosis factor retains bioactivity in the presence of neutralizing anti-tumor necrosis factor antibodies. , 1989, Journal of immunology.

[33]  C. A. Santos,et al.  Cytokine immunotherapy of cancer with controlled release biodegradable microspheres in a human tumor xenograft/SCID mouse model , 1998, Cancer Immunology, Immunotherapy.

[34]  B. Car,et al.  The Toxicology of Interleukin-12: A Review , 1999, Toxicologic pathology.

[35]  I. Fidler,et al.  Synergistic activation by recombinant mouse interferon-gamma and muramyl dipeptide of tumoricidal properties in mouse macrophages. , 1985, Journal of immunology.

[36]  E. Fikrig,et al.  TLR9-Targeted Biodegradable Nanoparticles as Immunization Vectors Protect against West Nile Encephalitis , 2010, The Journal of Immunology.

[37]  Soong Ho Um,et al.  Therapeutic cell engineering using surface-conjugated synthetic nanoparticles , 2010, Nature Medicine.

[38]  G Gregoriadis,et al.  The carrier potential of liposomes in biology and medicine (second of two parts). , 1976, The New England journal of medicine.

[39]  I. Fidler,et al.  Liposomal delivery of biological response modifiers to macrophages , 1991, Biotherapy.

[40]  I. Bakker-Woudenberg,et al.  Free versus liposome-encapsulated muramyl tripeptide phosphatidylethanolamide (MTPPE) and interferon-y (IFN-y) in experimental infection with Listeria Monocytogenes , 1993, Biotherapy.

[41]  Y. Perrie,et al.  Liposome-based cationic adjuvant formulations (CAF): Past, present, and future , 2009, Journal of liposome research.

[42]  R. K. Rana,et al.  Controlled Release of Interleukin-2 from Biodegradable Microspheres , 1990, Bio/Technology.

[43]  J Cohen,et al.  IL-12 Deaths: Explanation and a Puzzle , 1995, Science.

[44]  I. Fidler,et al.  Activation of tumoricidal properties in mouse macrophages by lymphokines encapsulated in liposomes. , 1979, Cancer research.

[45]  J. Benoit,et al.  Development and characterization of interleukin-18-loaded biodegradable microspheres. , 2006, International journal of pharmaceutics.

[46]  I. Fidler,et al.  In situ activation of murine macrophages by liposomes containing lymphokines. , 1980, Cellular immunology.

[47]  R. J. Kelleher,et al.  IL-12 delivered intratumorally by multilamellar liposomes reactivates memory T cells in human tumor microenvironments. , 2009, Clinical immunology.

[48]  H. Alpár,et al.  Protection against plague following immunisation with microencapsulated V antigen is reduced by co-encapsulation with IFN-gamma or IL-4, but not IL-6. , 2002, Vaccine.

[49]  J. Oppenheim,et al.  Cytokines: Past, Present, and Future , 2001, International journal of hematology.

[50]  C. Bucana,et al.  Cytokine-containing liposomes as adjuvants for HIV subunit vaccines. , 1995, AIDS research and human retroviruses.

[51]  M. Sabel,et al.  In situ tumor vaccination with interleukin-12-encapsulated biodegradable microspheres: induction of tumor regression and potent antitumor immunity. , 2000, Cancer research.

[52]  T. Fahmy,et al.  A comprehensive platform for ex vivo T-cell expansion based on biodegradable polymeric artificial antigen-presenting cells. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[53]  B. Narasimhan,et al.  Polyanhydride microparticles enhance dendritic cell antigen presentation and activation. , 2011, Acta biomaterialia.

[54]  Wim E. Hennink,et al.  Protein Instability in Poly(Lactic-co-Glycolic Acid) Microparticles , 2000, Pharmaceutical Research.

[55]  C. Bucana,et al.  Superior antiproliferative effects mediated by interferon-alpha entrapped in liposomes against a newly established human lung cancer cell line. , 1990, Journal of biological response modifiers.

[56]  C. Butts,et al.  L-BLP25: A Peptide Vaccine Strategy in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[57]  C. Alving,et al.  Liposomes as carriers of antigens and adjuvants. , 1991, Journal of immunological methods.

[58]  D. Crommelin,et al.  Liposomes Containing Interferon-Gamma as Adjuvant in Tumor Cell Vaccines , 2004, Pharmaceutical Research.

[59]  F. Dosio,et al.  Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential , 2006, International journal of nanomedicine.

[60]  L. Babiuk,et al.  Effect of IL-4 and IL-12 liposomal formulations on the induction of immune response to bovine herpesvirus type-1 glycoprotein D. , 1997, Vaccine.

[61]  M. Tsujimoto,et al.  Potential usage of thermosensitive liposomes for site-specific delivery of cytokines. , 2000, Cancer letters.

[62]  A. Bonetti,et al.  Pharmacokinetics of an extended-release human interferon alpha-2b formulation , 2004, Cancer Chemotherapy and Pharmacology.

[63]  S. Yuk,et al.  Polymeric protein delivery systems , 2007 .

[64]  M. Lohmann‐Matthes,et al.  Immunotherapy of murine visceral leishmaniasis with murine recombinant interferon-gamma and MTP-PE encapsulated in liposomes. , 1991, Journal of interferon research.

[65]  I. Fidler,et al.  Rat alveolar macrophages are susceptible to activation by free and liposome-encapsulated lymphokines. , 1980, Journal of immunology.

[66]  M. Nishio,et al.  Safety of BLP25 liposome vaccine (L-BLP25) in Japanese patients with unresectable stage III NSCLC after primary chemoradiotherapy: preliminary results from a Phase I/II study. , 2011, Japanese journal of clinical oncology.

[67]  Dennis E Discher,et al.  Polymersome carriers: from self-assembly to siRNA and protein therapeutics. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[68]  P. Ellis,et al.  A multicenter open-label study to assess the safety of a new formulation of BLP25 liposome vaccine in patients with unresectable stage III non-small-cell lung cancer. , 2010, Clinical lung cancer.

[69]  E. Abraham,et al.  Intranasal immunization with liposomes containing IL-2 enhances bacterial polysaccharide antigen-specific pulmonary secretory antibody response. , 1992, Journal of immunology.

[70]  W. Stewart,et al.  Binding and capture of human interferon-alpha by reverse evaporation vesicles, multilamellar vesicles, and small unilamellar vesicles. , 1981, Journal of interferon research.

[71]  M. D'souza,et al.  Sustained-release interleukin-12 microspheres in the treatment of cancer. , 1999, Drug development and industrial pharmacy.

[72]  A. Chang,et al.  Synergistic effect of intratumoral IL-12 and TNF-alpha microspheres: systemic anti-tumor immunity is mediated by both CD8+ CTL and NK cells. , 2007, Surgery.

[73]  D. Crommelin,et al.  Sustained cytokine delivery for anticancer vaccination: liposomes as alternative for gene-transfected tumor cells. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  P. Felgner,et al.  Biological activity of liposome-encapsulated murine interferon gamma is mediated by a cell membrane receptor. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[75]  R. Ho,et al.  Differential Disposition of Soluble and Liposome-Formulated Human Recombinant Interleukin-7: Effects on Blood Lymphocyte Population in Guinea Pigs , 1994, Pharmaceutical Research.

[76]  T. Fahmy,et al.  Pathogen-associated molecular patterns on biomaterials: a paradigm for engineering new vaccines. , 2011, Trends in biotechnology.

[77]  A. Duits,et al.  Immunoadjuvant activity of a liposomal IL-6 formulation. , 1993, Vaccine.

[78]  B. Conway,et al.  Immune responses to V antigen of Yersinia pestis co-encapsulated with IFN-gamma: effect of dose and formulation. , 1998, Vaccine.

[79]  T. Ohno,et al.  Controlled release of interleukin-2 for tumour immunotherapy using alginate/chitosan porous microspheres , 1997 .

[80]  Jason Park,et al.  Modulation of CD4+ T lymphocyte lineage outcomes with targeted, nanoparticle-mediated cytokine delivery. , 2011, Molecular pharmaceutics.

[81]  T. Tadakuma,et al.  Inhibition of growth of rat hepatoma by local injection of liposomes containing recombinant interleukin-2 , 1991, Biotherapy.

[82]  N. S. Postma,et al.  Treatment with liposome-bound recombinant human tumor necrosis factor-alpha suppresses parasitemia and protects against Plasmodium berghei k173-induced experimental cerebral malaria in mice. , 1999, The Journal of pharmacology and experimental therapeutics.

[83]  M. C. Popescu,et al.  Liposomal formulation of a self lymphoma antigen induces potent protective antitumor immunity. , 1998, Journal of immunology.

[84]  A. Eggermont,et al.  Pegylated liposomal tumor necrosis factor‐α results in reduced toxicity and synergistic antitumor activity after systemic administration in combination with liposomal doxorubicin (Doxil®) in soft tissue sarcoma‐bearing rats , 2002, International journal of cancer.

[85]  K. Griffith,et al.  Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-α in a model of metastatic breast cancer , 2010, Breast Cancer Research and Treatment.

[86]  I. Bakker-Woudenberg,et al.  Modulation of nonspecific antimicrobial resistance of mice to Klebsiella pneumoniae septicemia by liposome-encapsulated muramyl tripeptide phosphatidylethanolamine and interferon-gamma alone or combined. , 1995, The Journal of infectious diseases.

[87]  I. Fidler,et al.  Synergism between human recombinant gamma-interferon and muramyl dipeptide encapsulated in liposomes for activation of antitumor properties in human blood monocytes. , 1985, Cancer research.

[88]  D. Gridley,et al.  Liposome-encapsulated tumor necrosis factor-alpha enhances the effects of radiation against human colon tumor xenografts. , 2001, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[89]  I. Fidler,et al.  Human monocytes activated by immunomodulators in liposomes lyse herpesvirus-infected but not normal cells. , 1984, Science.

[90]  I. Fidler,et al.  Synergism between lymphokines and muramyl dipeptide encapsulated in liposomes: in situ activation of macrophages and therapy of spontaneous cancer metastases. , 1984, Journal of immunology.

[91]  M. Alonso,et al.  Biodegradable micro- and nanoparticles as long-term delivery vehicles for interferon-alpha. , 2003, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[92]  M. Bar‐eli,et al.  Delivery of interferon to intracellular pathways by encapsulation of interferon into multilamellar liposomes is independent of the status of interferon receptors. , 1994, Cytokine.

[93]  R. Langer,et al.  Polymers for the sustained release of proteins and other macromolecules , 1976, Nature.

[94]  M. Sabel,et al.  Neoadjuvant intratumoral cytokine‐loaded microspheres are superior to postoperative autologous cellular vaccines in generating systemic anti‐tumor immunity , 2006, Journal of surgical oncology.

[95]  P. Anderson,et al.  Cytokines in liposomes: preliminary studies with IL-1, IL-2, IL-6, GM-CSF and interferon-gamma. , 1994, Cytokine.

[96]  J. Cleland,et al.  Factors affecting the in vitro release of recombinant human interferon‐γ (rhIFN‐γ) from PLGA microspheres , 1997 .

[97]  Y. Barenholz,et al.  Delivery of Cytokines by Liposomes. II. Interleukin‐2 Encapsulated in Long‐Circulating Sterically Stabilized Liposomes: Immunomodulatory and Anti‐Tumor Activity in Mice , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[98]  Y. Perrie,et al.  Liposomal vaccine delivery systems , 2011, Expert opinion on drug delivery.

[99]  M. Atkins,et al.  Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[100]  W. Gillanders,et al.  Review: novel nonviral delivery approaches for interleukin-12 protein and gene systems: curbing toxicity and enhancing adjuvant activity. , 2006, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

[101]  Wah Chiu,et al.  Interbilayer-Crosslinked Multilamellar Vesicles as Synthetic Vaccines for Potent Humoral and Cellular Immune Responses , 2011, Nature materials.

[102]  E. Mathiowitz,et al.  Cytokines Delivered by Biodegradable Microspheres Promote Effective Suppression of Human Tumors by Human Peripheral Blood Lymphocytes in the SCID–Winn Model , 2000, Journal of immunotherapy.

[103]  M. Lohmann‐Matthes,et al.  Mouse interferon-gamma in liposomes: pharmacokinetics, organ-distribution, and activation of spleen and liver macrophages in vivo. , 1989, Journal of interferon research.

[104]  Mohamed A. Shaker,et al.  Interleukin-2: evaluation of routes of administration and current delivery systems in cancer therapy. , 2009, Journal of pharmaceutical sciences.

[105]  Y. Barenholz,et al.  Delivery of cytokines by liposomes. III. Liposome-encapsulated GM-CSF and TNF-alpha show improved pharmacokinetics and biological activity and reduced toxicity in mice. , 1997, Journal of immunotherapy.

[106]  M. C. Popescu,et al.  In situ vaccination against a non-immunogenic tumour using intratumoural injections of liposomal interleukin 2. , 2001, Cytokine.

[107]  W. Hennink,et al.  IL-2 loaded dextran microspheres with attractive histocompatibility properties for local IL-2 cancer therapy. , 2003, Cytokine.

[108]  Y. Barenholz,et al.  Immunogenicity and safety of a novel liposomal influenza subunit vaccine (INFLUSOME‐VAC) in young adults , 2003, Journal of medical virology.

[109]  P. Poindron,et al.  In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide. , 1996, The American journal of physiology.

[110]  E. Mathiowitz,et al.  Characterization of cytokine-encapsulated controlled-release microsphere adjuvants. , 2004, Cancer biotherapy & radiopharmaceuticals.

[111]  J. Irache,et al.  Gamma Interferon Loaded onto Albumin Nanoparticles: In Vitro and In Vivo Activities against Brucella abortus , 2007, Antimicrobial Agents and Chemotherapy.

[112]  F. Falkenberg,et al.  Cytokine depot formulations as adjuvants for tumor vaccines. I. Liposome-encapsulated IL-2 as a depot formulation. , 1999, Journal of immunotherapy.

[113]  Qiang Zhou,et al.  Treg versus Th17 lymphocyte lineages are cross-regulated by LIF versus IL-6 , 2009, Cell cycle.

[114]  W. Stewart,et al.  Altered pharmacological properties of liposome-associated human interferon-alpha. , 1982, Journal of virology.

[115]  Y. Barenholz,et al.  Delivery of cytokines by liposomes: hematopoietic and immunomodulatory activity of interleukin-2 encapsulated in conventional liposomes and in long-circulating liposomes. , 2000, Journal of immunotherapy.

[116]  P. Scott IL-12: initiation cytokine for cell-mediated immunity. , 1993, Science.

[117]  M. Ratain,et al.  Hyponatremia and other toxic effects during a phase I trial of recombinant human gamma interferon and vinblastine. , 1986, Cancer treatment reports.

[118]  R. Langer,et al.  Microparticulate formulations for the controlled release of interleukin-2. , 2004, Journal of pharmaceutical sciences.

[119]  D. Irvine,et al.  Bio-inspired, bioengineered and biomimetic drug delivery carriers , 2011, Nature Reviews Drug Discovery.

[120]  R. J. Kelleher,et al.  Human CD4+ Effector Memory T Cells Persisting in the Microenvironment of Lung Cancer Xenografts Are Activated by Local Delivery of IL-12 to Proliferate, Produce IFN-γ, and Eradicate Tumor Cells1 , 2005, The Journal of Immunology.

[121]  D. Fan,et al.  Antitumor effects of liposomal IL1α and TNFα against the pulmonary metastases of the B16F10 murine melanoma in syngeneic mice , 1995, Clinical & Experimental Metastasis.

[122]  I. Fidler,et al.  Involvement of macrophages in the eradication of established metastases following intravenous injection of liposomes containing macrophage activators. , 1982, Cancer research.

[123]  M. Choti,et al.  Controlled Local Delivery of Interleukin-2 by Biodegradable Polymers Protects Animals from Experimental Brain Tumors and Liver Tumors , 2001, Pharmaceutical Research.

[124]  P. Poindron,et al.  Preparation and characterization of interferon-γ-containing liposomes , 1995 .

[125]  Keunchil Park,et al.  INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer , 2011, BMC Cancer.

[126]  S. North,et al.  L-BLP25: a MUC1-targeted peptide vaccine therapy in prostate cancer , 2007, Expert opinion on biological therapy.

[127]  A. Chang,et al.  Intratumoral IL-12 and TNF-α–Loaded Microspheres Lead To Regression of Breast Cancer and Systemic Antitumor Immunity , 2004, Annals of Surgical Oncology.

[128]  I. Fidler,et al.  The role of plasma membrane receptors and the kinetics of macrophage activation by lymphokines encapsulated in liposomes. , 1981, Cancer research.

[129]  G. Storm,et al.  Immunoadjuvant activity of interferon-γ-liposomes co-administered with influenza vaccines , 2001 .

[130]  V. Torchilin Recent advances with liposomes as pharmaceutical carriers , 2005, Nature Reviews Drug Discovery.

[131]  S. Bernstein,et al.  Human CD4+ T Cells Present Within the Microenvironment of Human Lung Tumors Are Mobilized by the Local and Sustained Release of IL-12 to Kill Tumors In Situ by Indirect Effects of IFN-γ1 , 2003, The Journal of Immunology.

[132]  Y. Bae,et al.  Novel approaches in microparticulate PLGA delivery systems encapsulating proteins , 2007 .

[133]  Y. Barenholz,et al.  A novel liposomal influenza vaccine (INFLUSOME-VAC) containing hemagglutinin-neuraminidase and IL-2 or GM-CSF induces protective anti-neuraminidase antibodies cross-reacting with a wide spectrum of influenza A viral strains. , 2001, Vaccine.

[134]  E. Voronov,et al.  Macrophage activation for the production of immunostimulatory cytokines by delivering interleukin 1 via biodegradable microspheres. , 2000, Cytokine.

[135]  E. Chang,et al.  Induction of heat shock protein 70 protects intestinal epithelial IEC-18 cells from oxidant and thermal injury. , 1996, The American journal of physiology.

[136]  J. Berzofsky,et al.  Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function , 2005, The Journal of experimental medicine.

[137]  M. C. Popescu,et al.  Human Autologous Tumor-Specific T-Cell Responses Induced by Liposomal Delivery of a Lymphoma Antigen , 2004, Clinical Cancer Research.

[138]  I. Fidler Therapy of spontaneous metastases by intravenous injection of liposomes containing lymphokines. , 1980, Science.

[139]  P. Anderson,et al.  Depot characteristics and biodistribution of interleukin-2 liposomes: importance of route of administration. , 1992, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[140]  Sang-Nae Cho,et al.  Enhanced Immunogenicity and Protective Efficacy with the Use of Interleukin-12-Encapsulated Microspheres plus AS01B in Tuberculosis Subunit Vaccination , 2006, Infection and Immunity.

[141]  M. C. Popescu,et al.  A novel proteoliposomal vaccine induces antitumor immunity against follicular lymphoma. , 2007, Blood.

[142]  J. Vansteenkiste,et al.  Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[143]  G. Trinchieri,et al.  The adjuvant effect of interleukin-12 in a vaccine against Leishmania major , 1994 .

[144]  D. Crommelin,et al.  Liposomes as sustained release system for human interferon-gamma: biopharmaceutical aspects. , 2001, Biochimica et biophysica acta.

[145]  G. Storm,et al.  Liposomes as cytokine-supplement in tumor cell-based vaccines. , 1999, International journal of pharmaceutics.

[146]  A. Eggermont,et al.  Biodistribution and tumor localization of stealth liposomal tumor necrosis factor‐α in soft tissue sarcoma bearing rats , 1998, International journal of cancer.

[147]  M. Sabel,et al.  Cancer immunotherapy with interleukin 12 and granulocyte-macrophage colony-stimulating factor-encapsulated microspheres: coinduction of innate and adaptive antitumor immunity and cure of disseminated disease. , 2002, Cancer research.

[148]  G. Gregoriadis The Carrier Potential of Liposomes in Biology and Medicine , 1976 .

[149]  M. Sabel,et al.  Neoadjuvant therapy with interleukin-12-loaded polylactic acid microspheres reduces local recurrence and distant metastases. , 2001, Surgery.

[150]  Liposomes as immunological adjuvants , 1974 .

[151]  G. Gregoriadis,et al.  Interleukin-15 acts as an immunological co-adjuvant for liposomal antigen in vivo. , 1997, Immunology letters.

[152]  A. Olivi,et al.  Local Immunotherapy with Interleukin-2 Delivered from Biodegradable Polymer Microspheres Combined with Interstitial Chemotherapy: A Novel Treatment for Experimental Malignant Glioma , 2003, Neurosurgery.

[153]  P. Anderson,et al.  Increased local antitumor effects of interleukin 2 liposomes in mice with MCA-106 sarcoma pulmonary metastases. , 1990, Cancer research.